PET-CT como biomarcador da mastocitose sistêmica agressiva
PET-CT as a biomarker of the aggressive systemic mastocytosis
Henrikki Gomes Antila; Laís Souza Gomes; Grazielly de Fatima Pereira; Iandra Leite Perez; Danilo Gois Gonçalves; Rafael Bonamichi-Santos; Jorge Kalil; Pedro Giavina-Bianchi
Resumo
Relato de caso ilustrando como a tomografia computadorizada por emissão de pósitrons (PET-CT) pode ser um biomarcador dos casos agressivos de mastocitose.
Palavras-chave
Abstract
Case report showing that positron emission tomography computed tomography (PET-CT) may be a biomarker of aggressive mastocytosis.
Keywords
References
1. Theoharides TC, Valent P, Akin C. Mast Cells, Mastocytosis, and related disorders. N Engl J Med. 2015;373(2):163-172. doi:10.1056/ NEJMra1409760.
2. Valent P, Akin C, Metcalfe DD. Review Article Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420-8. doi:10.1182/blood-2016-09-731893. effective.
3. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009 Jun 4;113(23):5727-36.
4. Djelbani-Ahmed S, Chandesris MO, Mekinian A, Canioni D, Brouzes C, Hanssens K, et al. FDG-PET/CT findings in systemic mastocytosis: a French multicentre study. Eur J Nucl Med Mol Imaging. 2015;42(13):2013‑20. doi:10.1007/s00259-015-3117-3.
5. Tomihama RT, McEachen JC, Kuo PH. Imaging of systemic mastocytosis by FDG-PET/CT demonstrates increased activity in cortical bone. Clin Nucl Med. 2008;33(3):220-3. doi:10.1097/ RLU.0b013e3181638e5e.
6. Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, et al. Advances in the classification and treatment of mastocytosis: Current status and outlook toward the future. Cancer Res. 2017;77(6):1261‑70.
7. Stone RM, Manley PW, Larson RA, Capdeville R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2018;2(4):444-53. doi:10.1182/bloodadvances.2017011080.
8. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med. 2016;374(26):2530-41. doi:10.1056/ NEJMoa1513098.
Submitted date:
09/27/2018
Accepted date:
09/29/2018
Facebook
LinkedIn
Mendeley
StumbleUpon
Reddit
Email